Bayer Regeneron Eye Drug Meets Study Goal
By wchung | 17 Jun, 2026
Regeneron Pharmaceuticals Inc. and Bayer HealthCare AG said Thursday their developing VEGF Trap-Eye drug met key vision improvement goals in a midstage study.
The drug is aimed at improving vision in patients with diabetic macular edema. The condition is a disease of the retina that affects individuals with diabetes and can lead to blindness.
The study, which took place over 24 weeks, compared VEGF Trap-Eye with laser therapy.
The companies also said VEGF Trap-Eye was well tolerated, and there were no drug-related serious adverse events.
Shares of Regeneron, which is based in Tarrytown, N.Y., closed at $30.46 Wednesday. Bayer HealthCare AG is based in Germany.
2/18/2010 8:18 AM NEW YORK (AP)
© 2026 by Asian Media Group Inc.
Recent Articles
- US Holds off Blacklisting DeepSeek, Over 100 Firms Deemed Security Risks
- Vietnam Maintains 2026 GDP Target Despite Trade Deficit, Inflation Pressure
- China Makes New Push to Take Yuan Global
- Iran Deal Includes $300 Billion Investment Fund, With Over Half Already Committed
- US Senate Narrowly Blocks New Bid to Rein in Trump War Powers
- BYD Ramps up Battery Production in Brazil
- Intel Begins Chip Production with New Fabrication Process
- 'Wingman' Drone Key Piece of EU's Defense Self-Reliance
- Keiko Fujimori Edges Ahead in Brutal Contested Vote Count
- Chip Queen He Tingbo Subverts Moore's Law to Overturn the Global Semiconductor Hierarchy